uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Cardiol Unit, F-75877 Paris, France..
Canc Ctr Kansas, Wichita, KS USA..
Calif Pacific Med Ctr, San Francisco, CA USA..
Ghent Univ Hosp, Ghent, Belgium..
Show others and affiliations
2014 (English)In: Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, E-ISSN 1432-0843, Vol. 73, no 6, 1241-1252 p.Article in journal (Refereed) Published
Abstract [en]

This study assessed the cardiovascular safety of cabazitaxel, based on thorough evaluation of QT and non-QT variables, and the relationship between pharmacokinetic and pharmacodynamic electrocardiographic (ECG) profiles and the occurrence of Grade a parts per thousand yen3 cardiovascular adverse events. Patients with advanced solid tumors were treated with cabazitaxel 25 mg/m(2) every 3 weeks. Digital ECG recordings were obtained during Cycle 1 over 24 h after dosing. The primary end point was effect of cabazitaxel on QT interval corrected by the Fridericia formula (QTcF). Secondary end points were additional ECG parameters (QT, PR and QRS intervals, and heart rate), plasma pharmacokinetics of cabazitaxel and overall clinical safety. The pharmacodynamic (ECG) population included 94 patients. In 63 patients with a full 24-h ECG evaluation, the maximum upper bound of 90 % confidence interval (CI) for mean QTcF change from baseline was 7.46 ms (mean 4.8 ms), occurring at 1 h 30 min post-infusion. The slope of QTcF change from baseline versus cabazitaxel concentration was slightly negative (-0.012 [95 % CI -0.017; -0.008], equivalent to a 1.2 ms decrease per 100 ng/mL increase in cabazitaxel concentration). For non-QT variables, no effect was noted. No Grade a parts per thousand yen3 cardiac adverse events were observed; Grade a parts per thousand yen3 hypotension and lymphocele occurred in two patients and one patient, respectively. These results suggest that cabazitaxel has no clinically significant cardiovascular adverse effects in patients with advanced solid tumors.

Place, publisher, year, edition, pages
2014. Vol. 73, no 6, 1241-1252 p.
Keyword [en]
Cabazitaxel, QTc interval, Cardiac safety, Advanced solid tumors, Pharmacokinetics, ECG
National Category
Cardiac and Cardiovascular Systems
URN: urn:nbn:se:uu:diva-306351DOI: 10.1007/s00280-014-2460-6ISI: 000336395700016PubMedID: 24718982OAI: oai:DiVA.org:uu-306351DiVA: diva2:1040509
Available from: 2016-10-27 Created: 2016-10-27 Last updated: 2016-10-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Daugaard, GedskeYachnin, Jeffrey
In the same journal
Cancer Chemotherapy and Pharmacology
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 79 hits
ReferencesLink to record
Permanent link

Direct link